Payment overview · 2025
General Payments
$265.45
13 reported records · 7 companies
Healthcare provider profile · identity verified
Jaclyn Rene Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GILBERT, AZ · NPI 1396972444
Verified facts
What the public records show
CMS Open Payments records show Jaclyn Rene Brown, MD received $265.45 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.32 | 24.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.15 | 16.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.99 | 15.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.98 | 15.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.58 | 14.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.73 | 7.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.45 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 116 |
| Lisinopril | Lisinopril | 300 | 109 |
| Losartan Potassium | Losartan Potassium | 217 | 77 |
| Metformin Hcl Er | Metformin Hcl | 212 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 44 |
| Simvastatin | Simvastatin | 114 | 41 |
| Sertraline Hcl | Sertraline Hcl | 101 | 31 |
| Metformin Hcl | Metformin Hcl | 92 | 35 |
| Gabapentin | Gabapentin | 86 | 39 |
| Alendronate Sodium | Alendronate Sodium | 82 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 27 |
| Trazodone Hcl | Trazodone Hcl | 78 | 31 |
| Famotidine | Famotidine | 66 | 28 |
| Irbesartan | Irbesartan | 64 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 20 |
| Jardiance | Empagliflozin | 55 | 15 |
| Ozempic | Semaglutide | 54 | 14 |
| Montelukast Sodium | Montelukast Sodium | 50 | 20 |
| Bupropion Xl | Bupropion Hcl | 48 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 22 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Omeprazole | Omeprazole | 37 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Allopurinol | Allopurinol | 33 | 12 |
| Furosemide | Furosemide | 33 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 15 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Atenolol | Atenolol | 30 | 11 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 12 |
| Eliquis | Apixaban | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 14 |
| Propranolol Hcl | Propranolol Hcl | 28 | 14 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Estradiol | Estradiol | 26 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | 12 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.45 · 13 records | Abbott Laboratories | CAPVAXIVE, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GARDASIL 9, KRYSTEXXA, M-M-R II, NURTEC ODT, PROCLAIM, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VARIVAX, VAXNEUVANCE, VRAYLAR, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error